ClinicalTrials.gg
DrugBiologicalRead study by study

Sibeprenlimab clinical trials

Also written VIS649.

studies test it
8
open now
3
in phase 3
3
first study started
2018
ClinicalTrials.gov finds 8 studies for sibeprenlimab. How that becomes 8 here

Every study that search finds has been read, to see whether and how it gives sibeprenlimab. ClinicalTrials.gov counts as of Nov 16, 2026. How drug pages count

  1. 8Found by its intervention search · See all 8 hereIt also reads titles, arm labels, keywords and descriptions, and counts the drug’s other names. Of these, 8 name it in an intervention entry. The counts it shows beside each synonym overlap: a study writing two names counts under both.
  2. +1Give it under a name that search misses: a biosimilar’s code or a misspelling
  3. 9Give sibeprenlimab to participants
  4. −1Compare another treatment with it
  5. 8Test it: the count on this site

Get an email when these change. Save the sibeprenlimab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
25 Nov 2025 · VOYXACT · BLA 761434 (FDA, Drugs@FDA)
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Sibeprenlimab
5

Development codes

VIS649
4

Studies by the year they started

8 studies that test it; most in 2022 (3)

Studies that test sibeprenlimab, by start year
YearStudies
20181
20223
20241
20251
20262

By phase

A phase 1/2 study counts in both.

Phase 1
2
Phase 2
4
Phase 3
3

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 8 · Other 0

Otsuka Pharmaceutical Development & Commercialization, Inc. (7) · Otsuka Beijing Research Institute (1)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Tested against it · 1 phase 3 study under way

Sibeprenlimab is the comparator. A study of two new drugs counts under both.

  • 1Povetacicept · Vertex Pharmaceuticals Incorporated · next primary completion Dec 2027
Reaching primary completion within a year · 1

Studies that test sibeprenlimab.

Studies

Open first, then newest update. How each study uses sibeprenlimab has had a first review, but it may not be perfect: check the study record before relying on it for anything important, and report a problem from its row. Some give it without naming it in an intervention entry: those were found by reading the record.

Testing it · 8

Behind its US label · 1 — the studies the FDA label of VOYXACT describes

From the Clinical Studies section of VOYXACT (2026-03), as openFDA has it. A study the site does not hold is left out.

Tested on its own · 7 — no other medicine in its arm
Tested with established drugs · 1 — they are given beside it
As the comparator · 1 — what is tested is compared with sibeprenlimab

Codes

What other systems call sibeprenlimab · ClinicalTrials.gg INT002181

  • MeSH (NLM) C000731962sibeprenlimabOne source NLM
  • UNII (FDA) GHX28QZ7DDSIBEPRENLIMABConfirmed FDA, NLM
  • NCI Thesaurus C179120SibeprenlimabOne source FDA

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.

Start the discussion